Health investors from the United States are discovering vast prospects in Toronto as a hot-spot for biotech innovation and a place to invest in cutting-edge life sciences startups. To Jerel Davis, managing director of Versant Ventures, the global venture capital firm behind recent landmark deals in the city, “Toronto is pretty remarkable,” as a “completely under-tapped” market with strengths in fields ranging from regenerative medicine and oncology to heart disease, children’s health, radio medicine and imaging.
